Skip to main content
Fig. 8 | Arthritis Research & Therapy

Fig. 8

From: Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry

Fig. 8

Comparison of hazards of severer adverse event by treatment types. A Comparison among the D2T RA group. B Comparison among the b/tsDMARD-naïve group. TNFi was used as the reference. Nelson-Aalen cumulative hazard estimate was used. The result of Cox regression using TNFi was used as the reference. *p < 0.05. TNFi, tumour necrosis factor inhibitor; IL-6Ri, interleukin-6 receptor inhibitor; CTLA4-Ig, cytotoxic T-lymphocyte–associated antigen-4 immunoglobulin; JAKi, Janus kinase inhibitor; HR, hazard ratio

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us